Novo Nordisk's analysis of real-world data shows that patients who switched from obesity injections like Wegovy or Lilly's Zepbound to Novo's new Wegovy pill continued to lose weight, shedding about 4% of their body weight on average after three months. This suggests that patients may not need to rely on weekly injections indefinitely and can opt for the more convenient oral treatment. The study involved 194 patients and found improvements in weight loss, BMI reduction, and patient satisfaction. Novo also announced promising early results for its next-generation obesity drug CagriSema, which targets brain activity related to cravings and improves organ and bone health, with a launch expected early next year.
Novo Nordisk shares trade at USD 37.93 on Pluang as of Sep 30, 2026 17:02 WIB, down 0.99% for the day. This follows news of continued weight loss in patients switching from obesity injections to Novo's Wegovy pill, highlighting ongoing interest in the company's obesity treatments. Meanwhile, Eli Lilly shares are stable at USD 1,186.77, up 0.06%, reflecting steady investor confidence in its competing obesity drug portfolio.
